Univ.-Prof. Dr. Danilo Fliser

Werdegang

Wissenschaftspreise

Mitgliedschaft in wissenschaftlichen Gesellschaften/Organisationen

Mitgliedschaft im "Editorial Board" von Fachzeitschriften

National

• Der Nephrologe
• Nieren- und Hochdruckkrankheiten

International

• Journal of the American Society of Nephrology (JASN)
• Nephrology, Dialysis and Transplantation (NDT)
• Néphrologie & Thérapeutique (Deutscher Gasteditor)

Gutachtertätigkeit

Wissenschaftliche Organisationen

• Deutsche Forschungsgemeinschaft (DFG)
• Dutch Kidney Foundation (Nierstichting Nederland)
• Kidney Research UK
• Welcome Trust 
• The Scientific and Technological Research Council of Turkey (TÜBİTAK)

Zeitschriften

• American Journal of Hypertension (AJH)
• American Journal of Kidney Diseases (AJKD)
• American Journal of Physiology - Renal (AJP)  
• Archives of Internal Medicine (AIM)
• Arteriosclerosis Thrombosis and Vascular Biology (ATVB)
• Circulation
• Clinical Nephrology (CN)
• Clinical Science (CS)
• European Heart Journal (EHJ)
• European Journal of Clinical Investigation (EJCI)
• Hypertension
• Intensive Care Medicine
• Journal of the American College of Cardiology (JACC)
• Journal of the American Geriatrics Society (JAGS)
• Journal of the American Medical Association (JAMA)
• Journal of the American Society of Nephrology (JASN)
• Journal of Hypertension (JH)
• Kidney International
• Nephrology, Dialysis and Transplantation (NDT)
• Nephron
• New England Journal of Medicine (NEJM)
• Pediatric Nephrology

Meist zitierte Publikationen (> 100 Zitate) 

Bahlmann FH, de Groot K, Spandau J, Landry A, Hertel B, Duckert T, Bohm S, Menne J, Haller H, Fliser D.

Erythropoietin regulates endothelial progenitor cells.

Blood 2004; 103: 921-926

Landmesser U, Bahlmann FH, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, de Groot K, Fliser D, Fauler G, März W, Drexler H.

Simvastatin vs. Ezetimibe: Pleiotropic vs. lipid lowering effects on endothelial function and endothelial progenitor cells in humans.

Circulation 2005; 111: 2356-2363

Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D.

Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.

J Am Soc Nephrol 2002; 13: 170-176

Fliser D, Buchholz K, Haller H; for the EUTOPIA investigators (European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis).

Anti-inflammatory effects of angiotensin II subtype 1-receptor blockade in hypertensive patients with micro-inflammation.

Circulation 2004: 110: 1103-1107

Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Hoper M, Frolich JC, Haller H, Fliser D.

Cardiovascular effects of systemic NO synthase inhibition with asymmetric dimethylarginine in humans.

Circulation 2004; 109: 172-177

Fliser D, Ritz E.

Serum cystatin C concentration as a marker of renal dysfunction in the elderly.

Am J Kidney Dis 2001: 37: 79-83

Fliser D, Franek E, Joest M, Block S, Mutschler E, Ritz E.

Renal function in the elderly - influence of hypertension and cardiac function.

Kidney Int 1997; 51: 1196-1204

Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Franek E, Ritz E.

Insulin resistance and hyperinsulinaemia are already present in patients with incipient renal disease.

Kidney Int 1998; 53: 1243-1247

Bahlmann FH, de Groot K, Duckert T, Niemczyk E, Bahlmann E, Boehm SM, Haller H, Fliser D.

Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin.

Kidney Int2003; 64: 1648-1652

Bahlmann F, De Groot K, Mueller O, Hertel B, Haller H, Fliser D.

Stimulation of endothelial precursor cells: a novel therapeutic aspect of angiotensin II blockade.

Hypertension 2005; 45: 526-529

Weissinger EM, Wittke S, Kaiser T, Haller H, Bartel S, Krebs R, Golovko I, Rupprecht HD, Haubitz M, Hecker H, Mischak H, Fliser D.

Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes.

Kidney Int 2004; 65: 2426-2434

Rifai K, Ernst T, Kretschmer U, Bahr M, Hafer C, Haller H, Manns MP, Fliser D.

Prometheus - a new extracorporeal device for the treatment of liver failure.

J Hepatol 2003; 39: 984-990

Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E.

Asymmetric dimethylarginine predicts progression in patients with primary kidney diseases.

J Am Soc Nephrol 2005; 16: 2456-2461

Wittke S, Fliser D, Haubitz M, Bartel S, Krebs R, Hausadel F, Hillmann M, Golovko I, Koester P,  Haller H, Kaiser T, Mischak H, Weissinger EM.

Determination of peptides and proteins in human urine with capillary electrophoresis‑mass spectrometry, a suitable tool for the establishment of new diagnostic markers.

J Chromatogr A 2003; 1013: 173-181

Mischak H, Apweiler R, Banks R, Conaway M, Coon J, Dominiczak A, Ehrich JHH, Fliser D, Girolami M, Jankowski J, Julian B, Kolch W, Massy Z, Novak J, Peter KH, Rossing K, Schanstra J, Theodorescu D, Thongboonkerd V, Weissinger E.

Clinical Proteomics: a need to define the field and to begin to set adequate standards.

Proteomics - Clinical Applications 2007; 1: 148-156

Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A, Knüppel S, Haller H, Fliser D.

Proteomic analysis for the assessment of diabetic renal damage in humans.

Clin Sci 2004: 107: 485-495

Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D.

Asymmetric dimethylarginine (ADMA), renal perfusion and blood pressure in elderly subjects.

Circulation 2003; 107: 1891-1895

Becker J, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D.

Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney diseases. The Mild to Moderate Kidney Disease (MMKD) Study.

J Am Soc Nephrol 2005; 16: 1091-1098

Hirsch Faktor:41 

"Invited lecture" bei nationalen nephrologischen Gesellschaften

• Israel
• Italien
• Japan
• Russland
• Saudi Arabien
• USA